Krystal Biotech (KRYS) Tax Provisions (2023 - 2026)

Krystal Biotech has disclosed Tax Provisions across 4 years of filings, most recently posting $5.5 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at $5.5 million, down 29.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.8 million (down 226.59% YoY), and the FY2025 annual result was -$15.4 million, down 347.86% from the prior year.
• Tax Provisions came in at $5.5 million for Q1 2026 at Krystal Biotech, up from -$269000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $8.4 million in Q2 2025 to a low of -$31.4 million in Q3 2025.
• The 4-year median for Tax Provisions is $2.6 million (2024), against an average of -$196111.1.
• Peak annual rise in Tax Provisions reached 1661.01% in 2025, while the deepest fall reached 1312.75% in 2025.
• Krystal Biotech's Tax Provisions stood at $2.0 million in 2023, then surged by 57.61% to $3.1 million in 2024, then plunged by 108.69% to -$269000.0 in 2025, then jumped by 2148.33% to $5.5 million in 2026.
• The last three Tax Provisions figures came in at $5.5 million (Q1 2026), -$269000.0 (Q4 2025), and -$31.4 million (Q3 2025), per Business Quant data.